RVMD, BE, and a Copper Play Walk Into a Bar — Nobody's Heard of Two of Them

$RVMD — Revolution Medicines — is the worst-kept secret in biotech right now, but somehow still under the radar for most retail investors. Their pancreatic cancer drug Daxon Rasib posted Phase 3 data showing a 60% reduction in risk of death and survival time doubling from 6 to 13 months. It got a standing ovation at ASCO 2025 — literally before the presentation finished. Bloomberg Intelligence pegs the addressable market at nearly $5 billion, and the company already holds a special review voucher that could compress FDA approval to just 1-2 months. Rolling submission is underway. This is not a rumor.

$BE — Bloom Energy — showed up in IBD's breakaway gap analysis as a textbook institutional accumulation event on April 14th, 2026. When the smart money breaks out a chart like that, it usually means something structural changed in the business. Bloom makes solid oxide fuel cells for on-site power generation — think data centers, hospitals, and campuses that can't afford grid instability. With AI infrastructure demand exploding and every hyperscaler desperately hunting for reliable, off-grid power solutions, Bloom is positioned in exactly the right lane at exactly the right time.

The copper angle: Bloomberg's sourced expert is calling a 300,000-400,000 ton global shortfall with prices potentially exceeding $15,000/ton. The thesis keeps pointing toward DRC-based miners with ore grades of 2-6% versus South America's anemic 0.7-0.9% — that's not a marginal advantage, that's a different sport entirely. If you're hunting copper exposure with real leverage to the supply crunch, the names drilling in the DRC right now are where the asymmetry lives. Three picks, zero household names — that's how hidden gems are supposed to work.